SAREPTA THERAPEUTICS, INC. Proceeds from Sale of Available-for-sale Securities
SAREPTA THERAPEUTICS, INC. (SRPT) reported Proceeds from Sale of Available-for-sale Securities of $20.00 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2020-08-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2020-08-05
- SAREPTA THERAPEUTICS, INC. proceeds from sale of available-for-sale securities for the quarter ending 2019-06-30 was -$22.30M.
- SAREPTA THERAPEUTICS, INC. proceeds from sale of available-for-sale securities for the quarter ending 2019-03-31 was $42.30M.
- SAREPTA THERAPEUTICS, INC. proceeds from sale of available-for-sale securities for the quarter ending 2017-03-31 was $80.00M, a 280.95% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. proceeds from sale of available-for-sale securities for the quarter ending 2016-12-31 was -$1.00K, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. proceeds from sale of available-for-sale securities for fiscal 2016 was $112.10M, a 39.71% decline from fiscal 2015.
- SAREPTA THERAPEUTICS, INC. proceeds from sale of available-for-sale securities for fiscal 2015 was $185.94M, a 37.82% increase from fiscal 2014.
- SAREPTA THERAPEUTICS, INC. proceeds from sale of available-for-sale securities for fiscal 2014 was $134.91M.
| Period end | Proceeds from Sale of Available-for-sale Securities 3 month | Proceeds from Sale of Available-for-sale Securities 6 month | Proceeds from Sale of Available-for-sale Securities 9 month | Proceeds from Sale of Available-for-sale Securities 12 month | Proceeds from Sale of Available-for-sale Securities 404 month |
|---|---|---|---|---|---|
| 2019-06-30 | -$22.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $20.00M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $42.30M 10-Q · filed 2020-05-06 | ||||
| 2017-03-31 | $80.00M 10-Q · filed 2017-05-04 | $80.00M derived: sum of 2 quarters · filed 2017-05-04 | $91.39M derived: sum of 3 quarters · filed 2017-05-04 | $171.10M derived: sum of 4 quarters · filed 2017-05-04 | |
| 2016-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $11.39M derived: sum of 2 quarters · filed 2017-02-28 | $91.10M derived: sum of 3 quarters · filed 2017-02-28 | $112.10M 10-K · filed 2017-02-28 | |
| 2016-09-30 | $11.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $91.10M derived: sum of 2 quarters · filed 2016-11-07 | $112.10M 10-Q · filed 2016-11-07 | $156.19M derived: sum of 4 quarters · filed 2017-05-04 | |
| 2016-06-30 | $79.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $100.71M 10-Q · filed 2016-08-09 | $144.80M derived: sum of 3 quarters · filed 2017-05-04 | $188.00M derived: sum of 4 quarters · filed 2017-05-04 | |
| 2016-03-31 | $21.00M 10-Q · filed 2017-05-04 | $65.08M derived: sum of 2 quarters · filed 2017-05-04 | $108.29M derived: sum of 3 quarters · filed 2017-05-04 | $162.19M derived: sum of 4 quarters · filed 2017-05-04 | |
| 2015-12-31 | $44.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $87.29M derived: sum of 2 quarters · filed 2017-02-28 | $141.19M derived: sum of 3 quarters · filed 2017-02-28 | $185.94M 10-K · filed 2017-02-28 | |
| 2015-09-30 | $43.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $97.10M derived: sum of 2 quarters · filed 2016-11-07 | $141.85M 10-Q · filed 2016-11-07 | $190.17M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-06-30 | $53.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $98.65M 10-Q · filed 2016-08-09 | $146.96M derived: sum of 3 quarters · filed 2017-02-28 | $184.89M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-03-31 | $44.75M 10-Q · filed 2016-05-05 | $93.06M derived: sum of 2 quarters · filed 2017-02-28 | $130.99M derived: sum of 3 quarters · filed 2017-02-28 | ||
| 2014-12-31 | $48.31M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $86.24M derived: sum of 2 quarters · filed 2017-02-28 | $134.91M 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $37.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $86.60M 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | $48.67M 10-Q · filed 2015-08-06 | ||||
| 2014-03-31 | $117.72M 10-Q · filed 2014-05-08 | ||||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | |||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |